Newer medications like Lubiprostone, serotonin agonists like Cisapride and Tegaserod, Prucalopride, Linaclotide (a guanylate cyclase C receptor agonist) and Naloxone (opioids antagonist).

ZELNORM ® (tegaserod) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).

Alfasigma announced the withdrawal of the New Drug Application (NDA) for Zelnorm ® (tegaserod). The Company will no longer make the product available in the US marketplace. Zelnorm, a selective ...

COVINGTON, La., June 30, 2022 /PRNewswire/ -- Alfasigma USA, Inc. announces the withdrawal of the NDA for ZELNORM ® (tegaserod) effective June 30th. Alfasigma USA, Inc. will no longer make the product ...

Dr Shah, and team conveyed that this study was effective in evaluating the efficacy of Tegaserod revealing 6 mg Tegaserod b.i.d. reduced IBS-C symptoms in overall and US Food and Drug Administration ...

In 2002, tegaserod was approved by the United States Food and Drug Administration (FDA) for the short-term treatment of women with IBS-C. In 2007, tegaserod was voluntarily withdrawn from the market ...

Tegaserod is a safe and effective treatment option for irritable bowel syndrome with constipation (IBS-C) in women aged less than 65 years with no history of cardiovascular ischemic (CVI) events, ...

Tegaserod maleate, a 5-hydroxytryptamine 4-receptor partial agonist, was approved for treatment of constipation-type irritable bowel syndrome or functional constipation (6). In recent years, tegaserod ...

To assess in vivo anti-tumor activity of Tegaserod, syngeneic intravenous and subcutaneous melanoma xenografts were used. Immunocytochemical staining was performed to detect expression of active ...